Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
This is written in the approval document as:
Extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | ER positive, HER2-positive, PR positive | Invasive Breast Carcinoma | Neratinib | |
| HSE (1) | ER positive, HER2-positive | Invasive Breast Carcinoma | Neratinib | |
| HSE (1) | HER2-positive, PR positive | Invasive Breast Carcinoma | Neratinib | |
| HSE (1) | ER positive, ERBB2 amplification, PR positive | Invasive Breast Carcinoma | Neratinib | |
| HSE (1) | ER positive, ERBB2 amplification | Invasive Breast Carcinoma | Neratinib | |
| HSE (1) | ERBB2 amplification, PR positive | Invasive Breast Carcinoma | Neratinib |